CytoDyn to Showcase Leronlimab Data at AACR 2026
Event summary
- CytoDyn will present two posters at the AACR Annual Meeting 2026, April 17–22, in San Diego.
- Posters focus on leronlimab's potential in metastatic triple-negative breast cancer (mTNBC) and colorectal cancer (mCRC).
- Presentations scheduled for April 19 and April 21, with details available on CytoDyn’s website post-event.
The big picture
CytoDyn’s AACR presentations highlight its focus on leronlimab, a CCR5-targeting antibody, in difficult-to-treat cancers. The company is positioning itself in the growing oncology space, where immune-based therapies are gaining traction. Success in these indications could differentiate CytoDyn in a crowded market, but competition and clinical hurdles remain significant.
What we're watching
- Clinical Validation
- Whether leronlimab's data at AACR 2026 will validate its potential in mTNBC and mCRC.
- Strategic Positioning
- How CytoDyn leverages these findings to advance leronlimab in competitive oncology markets.
- Regulatory Pathway
- The pace at which CytoDyn progresses leronlimab through clinical trials and potential approvals.
Related topics